Abstract Search

ea0032p901 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Efficacy and safety of lanreotide in combination with pegvisomant in clinical practice in patients with active acromegaly with monotherapy failure

Venegas Eva , Lucas Tomas , Marazuela Monica , Cuatrecasas Guillem , Galvez Maria Angeles , Romero Enrique , Morales Francisco , Webb Susan M , Biaggeti Betina , Diaz Juan Jose , Mato Jose Antonio , Vilchez Ricardo , Bernabeu Ignacio , Paja Miguel , Pico Antonio , Domingo Manuel Puig , Soto Alfonso , on behalf of ACROCOMB study group

Introduction: ACROCOMB is a retrospective Spanish Multicenter study, designed to evaluate the efficacy (extent of tumour control) and safety of lanreotide (LAN) treatment combined with pegvisomant (PEG) or cabergoline in acromegalic patients with monotherapy failure.Methods: patients with acromegaly treated with LAN+PEG (45% of ACROCOMB patients) at 44 Spanish Endocrinology Departments were analysed.Results: 40% of patients were ma...

0 shares

ea0073oc7.4 | Oral Communications 7: Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Liver GPR55 regulates NAFLD progression from steatosis to fibrosis

Fernández Uxía , Fernández Fondevila Marcos , González Rellán María Jesús , Da Silva Lima Natalia , Buque Xabier , González Rodríguez Marta , Delgado Teresa , Varela Rey Marta V , Eva Novoa , Tojo Marta , Marta Miguel , Diéguez Carlos , Diéguez Miguel , DiéguezMaría Luísa , Arrese Marco , García-Monzón Carmelo , Mato Jose , Aspichueta Jose , Nogueiras Rubén

Background and aimsG protein-coupled receptor 55 (GPR55) is a putative cannabinoid receptor, and l-α-lysophosphatidylinositol (LPI) is its only known endogenous ligand. Although GPR55 has been linked to energy homeostasis in different organs, its specific role in lipid metabolism in the liver and its contribution to the pathophysiology of non-alcoholic fatty liver disease (NAFLD) remains unknown.MethodWe...

0 shares

ea0073oc7.5 | Oral Communications 7: Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Hepatic O-GlcNAcylated-p53 as a hub integrating the glucose counterregulatory response and insulin-suppressed gluconeogenesis

González Rellán María Jesús , Fernández Fondevila Marcos , Fernández Paz Uxia , Rodríguez Amaia , Varela Rey Marta , Veyrat-Durebex Christelle , Seoane Samuel , Bernardo Ganeko , Fernando Lopitz Otsoa , Fernandez Ramos David F , Bilbao Jon , Iglesias Cristina , Müller David F , Herzig Stephan , Martinez Chantar Maria Luz , Perez Fernandez Roman , Lopez Miguel , Diéguez Roman , Maria Mato Jose , Millet Oscar , Coppari Roberto , Woodhoo Ashwin , Fruhbeck Gema , Nogueiras Pozo Rubén

Background and aimsGlucose homeostasis is essential for life. The liver is among the key tissues for maintaining an adequate metabolic homeostasis and its alterations are at the root of the pathogenesis of many disease states. A perfect balance between glucose production, mainly at the liver, and glucose consumption in different tissues, is provided by the action of insulin and counterregulatory hormones as glucagon, cortisol or catecholamines. There is ...

0 shares

Endocrine Abstracts

Efficacy and safety of lanreotide in combination with pegvisomant in clinical practice in patients with active acromegaly with monotherapy failure

Liver GPR55 regulates NAFLD progression from steatosis to fibrosis

Hepatic O-GlcNAcylated-p53 as a hub integrating the glucose counterregulatory response and insulin-suppressed gluconeogenesis

BiosciAbstracts